Product Description
Cebranopadol is a novel first-in-class analgesic with highly potent agonistic activity at nociceptin/orphanin FQ peptide (NOP) and opioid receptors. It is highly potent and efficacious across a broad range of preclinical pain models. Its side effect profile is better compared to typical opioids. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30927089/)
Mechanisms of Action: OPR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Tris Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Netherlands, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Acute Pain
Phase 1: Healthy Volunteers|Hypercapnia|Pain Unspecified|Substance Abuse Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ALLEVIATE2 | P3 |
Recruiting |
Acute Pain |
2025-02-01 |
|
| ALLEVIATE1 | P3 |
Active, not recruiting |
Acute Pain |
2024-12-01 |
|
| TRN-228-102 | P1 |
Active, not recruiting |
Substance Abuse Unspecified|Healthy Volunteers |
2024-11-06 |
|
| PARK-104-VRH | P1 |
Completed |
Hypercapnia |
2023-03-30 |
43% |